These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21415160)

  • 21. Dual renin-angiotensin system blockade for nephroprotection.
    Ruggenenti P
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pentoxifylline in management of proteinuria in diabetic nephropathy.
    Tripathi K; Prakash J; Appaiha D; Srivastava PK
    Nephron; 1993; 64(4):641-2. PubMed ID: 8366994
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of intrarenal renin-angiotensin system activity in diabetic versus non-diabetic patients with overt proteinuria.
    Park JH; Jang HR; Lee JH; Lee JE; Huh W; Lee KB; Kwon YJ; Do JY; Kim HY; Kim YG
    Nephrology (Carlton); 2015 Apr; 20(4):279-85. PubMed ID: 25522682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Research into the glomerular podocyte--is it relevant to diabetic nephropathy?
    White KE
    Diabet Med; 2006 Jul; 23(7):715-9. PubMed ID: 16842474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The end of the road for dual renin-angiotensin system blockade in diabetic nephropathy: which way now?
    Advani A
    Can J Diabetes; 2014 Oct; 38(5):292-5. PubMed ID: 25172268
    [No Abstract]   [Full Text] [Related]  

  • 26. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
    Barnas U; Mayer G
    Wien Klin Wochenschr; 1995; 107(1):10-4. PubMed ID: 7871784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comments on 'in patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria'.
    Mitrovic JS; Lezaic V
    Kidney Int; 2010 Nov; 78(10):1049; author reply 1049. PubMed ID: 21030977
    [No Abstract]   [Full Text] [Related]  

  • 28. [Why does the patient lose protein? The state of the vessels is reflected in the urine].
    MMW Fortschr Med; 2008 Oct; 150(40):18. PubMed ID: 18990880
    [No Abstract]   [Full Text] [Related]  

  • 29. Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy.
    Ogawa S; Nako K; Okamura M; Senda M; Mori T; Ito S
    Hypertens Res; 2011 Mar; 34(3):400-1. PubMed ID: 21160485
    [No Abstract]   [Full Text] [Related]  

  • 30. Diabetic nephropathy: the proteinuria hypothesis.
    Williams ME
    Am J Nephrol; 2005; 25(2):77-94. PubMed ID: 15746541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis.
    Weidmann P; Schneider M; Böhlen L
    Nephrol Dial Transplant; 1995 Oct; 10 Suppl 9():39-45. PubMed ID: 8643207
    [No Abstract]   [Full Text] [Related]  

  • 32. Common Drugs for Stabilization of Renal Function in the Progression of Diabetic Nephropathy and Their Relations with Hypertension Therapy.
    Wang Y; Wang C; Zhang X; Gu HF; Wu L
    Curr Diabetes Rev; 2018; 14(2):149-161. PubMed ID: 28201968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atrasentan for the treatment of diabetic nephropathy.
    Egido J; Rojas-Rivera J; Mas S; Ruiz-Ortega M; Sanz AB; Gonzalez Parra E; Gomez-Guerrero C
    Expert Opin Investig Drugs; 2017 Jun; 26(6):741-750. PubMed ID: 28468519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
    Ivory SE; Packham DK; Reutens AT; Wolfe R; Rohde RD; Lewis J; Atkins RC;
    Nephrology (Carlton); 2013 Jul; 18(7):516-24. PubMed ID: 23506627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy.
    Kimura S; Inoguchi T; Yokomizo H; Maeda Y; Sonoda N; Takayanagi R
    Diabetes Obes Metab; 2012 Jul; 14(7):666-9. PubMed ID: 22268518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial.
    Ghorbani A; Omidvar B; Beladi-Mousavi SS; Lak E; Vaziri S
    Nefrologia; 2012; 32(6):790-6. PubMed ID: 23169362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual renin-angiotensin-aldosterone system inhibition: boon or bust?
    Hirsch S
    Int J Clin Pract; 2010 Sep; 64(10):1337-40. PubMed ID: 20716140
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.